Genialis Launches First-in-Class Biomarker to Predict Tumor Response and Clinical Benefit to KRAS Inhibitors
Genialis Introduces RNA- and ML-Based Biomarker Genialis™ krasID at [...]
Genialis™ krasID: Biology-driven Machine Learning to Personalize KRAS Inhibitor Therapy
KRAS inhibitors (KRASi) have the potential to transform treatment [...]
Genialis Named Finalist for Biotech Innovation Award at Biotech Week Boston
Company recognized for advances in RNA- and AI-based diagnostic [...]
Zola-007: Giving T-cells the license to kill | TPM podcast #38
Genialis’ Upcoming Events Genialis™ krasID [...]
RNA Biomarker Company Genialis Attends BIO Asia to Grow Collaborations in Taiwan
Company looks to expand partnerships and presence across Asia [...]
Cell therapy for T-cell malignancies—the science and business of developing curative medicines for patients in need | TPM podcast #37
Genialis’ Upcoming Events Genialis™ krasID [...]
Pharma Oncology Development Veteran Krista McKerracher Named Chairperson of the Board for Genialis
With a career dedicated to delivering firsts in medicine [...]
Genialis and Pancreatic Cancer Action Network (PanCAN) Partner to Progress KRAS Diagnostics
PanCAN’s Know Your Tumor precision medicine service will be [...]
Tackling healthcare disparities and bridging the digital divide: it doesn’t have to be so hard | TPM podcast #36
Genialis’ Upcoming Events Genialis™ krasID [...]
KRAS Drug Market and the Biomarker Opportunity
Highlights Mutated RAS genes have been known significant [...]
